Patent · US Expired

Double stranded DNA inhibitor of IRF-1 activity

US7524949B2 · kind B2 · utility

8Cited by
1References
2Claims
0Family size

Assignee

Inventors

Key dates

Filing dateOct 4, 2001
Grant dateApr 28, 2009
Priority date—
Expiry dateNov 4, 2023

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2310/341
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention refers to inhibitors of the transcription factors IRF-1, their use as therapeutic agents as well as their use for prevention and therapy of cardiovascular complications like re-stenosis after percutaneous angioplasty or stenosis of venous bypasses, chronic (transplant arteriosclerosis or vasculopathy) or acute transplant rejection, graft versus host disease (GVHD), immunological hypersensitivity reactions (allergies), particularly bronchial asthma and atopic dermatitis, chronic recurrent inflammatory diseases, particularly ulcerative colitis and Crohn's disease, psoriasis and sarcoidosis, as well as autoimmune diseases, particularly diabetes mellitus, multiple sclerosis, collagenoses (e. g. systemic lupus erythematodes), rheumatoid arthritis and vasculotids.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.